Preclinical development of HQP1351, a multikinase inhibitor targeting a broad spectrum of mutant KIT kinases, for the treatment of imatinib-resistant gastrointestinal stromal tumors
Xuechao Liu(Qingdao University), Yifan Zhai(Ascepion Pharmaceuticals (China))
Cited by 17